AusCann Group Holdings Ltd researches, develops, and commercializes various cannabinoid-derived therapeutic products for humans and animals in Australia and internationally.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.089|
|52 Week High||AU$0.084|
|52 Week Low||AU$0.30|
|1 Month Change||0%|
|3 Month Change||-15.24%|
|1 Year Change||-36.43%|
|3 Year Change||-88.13%|
|5 Year Change||n/a|
|Change since IPO||-59.55%|
Recent News & Updates
|AC8||AU Pharmaceuticals||AU Market|
Return vs Industry: AC8 underperformed the Australian Pharmaceuticals industry which returned 4.9% over the past year.
Return vs Market: AC8 underperformed the Australian Market which returned 20.3% over the past year.
Stable Share Price: AC8 is less volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: AC8's weekly volatility has decreased from 12% to 5% over the past year.
About the Company
AusCann Group Holdings Ltd researches, develops, and commercializes various cannabinoid-derived therapeutic products for humans and animals in Australia and internationally. It offers tetrahydrocannabinol and cannabidiol powder-based hard-shell capsules using Neuvis technology platform for the treatment of pain and related indications; CPAT-01, a liquid, oral veterinary medicine to treat pain and inflammation in dogs; and DermaCann, a liquid oral oil formulation containing CBD for healthy skin and immune function in dogs. The company is headquartered in West Perth, Australia.
AusCann Group Holdings Fundamentals Summary
|AC8 fundamental statistics|
Is AC8 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|AC8 income statement (TTM)|
|Cost of Revenue||AU$5.61m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
Oct 29, 2021
|Earnings per share (EPS)||-0.024|
|Net Profit Margin||-587.42%|
How did AC8 perform over the long term?See historical performance and comparison
Is AusCann Group Holdings undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate AC8's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate AC8's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: AC8 is unprofitable, so we can't compare its PE Ratio to the Oceanic Pharmaceuticals industry average.
PE vs Market: AC8 is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate AC8's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: AC8 is good value based on its PB Ratio (0.9x) compared to the AU Pharmaceuticals industry average (3.5x).
How is AusCann Group Holdings forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as AusCann Group Holdings has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has AusCann Group Holdings performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: AC8 is currently unprofitable.
Growing Profit Margin: AC8 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: AC8 is unprofitable, but has reduced losses over the past 5 years at a rate of 5% per year.
Accelerating Growth: Unable to compare AC8's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AC8 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (17.4%).
Return on Equity
High ROE: AC8 has a negative Return on Equity (-23.8%), as it is currently unprofitable.
How is AusCann Group Holdings's financial position?
Financial Position Analysis
Short Term Liabilities: AC8's short term assets (A$15.2M) exceed its short term liabilities (A$651.8K).
Long Term Liabilities: AC8's short term assets (A$15.2M) exceed its long term liabilities (A$39.9K).
Debt to Equity History and Analysis
Debt Level: AC8 is debt free.
Reducing Debt: AC8 has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AC8 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: AC8 has less than a year of cash runway if free cash flow continues to reduce at historical rates of 29.8% each year
What is AusCann Group Holdings's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate AC8's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate AC8's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if AC8's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AC8's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of AC8's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. Layton Patrick Mills is Chief Executive Officer at AusCann Group Holdings Ltd since March 18, 2021. He Founded Cannpal Animal Therapeutics Limited and serves as its Managing Director and Director. Mr....
CEO Compensation Analysis
Compensation vs Market: Layton's total compensation ($USD155.45K) is below average for companies of similar size in the Australian market ($USD301.95K).
Compensation vs Earnings: Insufficient data to compare Layton's compensation with company performance.
Experienced Management: AC8's management team is not considered experienced ( 0.6 years average tenure), which suggests a new team.
Experienced Board: AC8's board of directors are not considered experienced ( 1 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 39%.
AusCann Group Holdings Ltd's employee growth, exchange listings and data sources
- Name: AusCann Group Holdings Ltd
- Ticker: AC8
- Exchange: ASX
- Founded: NaN
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$39.209m
- Shares outstanding: 440.55m
- Website: https://auscann.com.au
- AusCann Group Holdings Ltd
- 35 Havelock Street
- Level 5
- West Perth
- Western Australia
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/19 15:53|
|End of Day Share Price||2021/10/19 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.